Bruno Crestani

Bruno Crestani

Auto-generated profile, based on publicly available information

Bruno Crestani

Service de Pneumologie, Allergologie et Transplantation, AP-HP, Hôpital Bichat Claude Bernard, Paris, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
GRGanesh Raghu
Ganesh Raghu
MRMartine Remy-Jardin
Martine Remy-Jardin
LRLuca Richeldi
Luca Richeldi
CTCarey C. Thomson
Carey C. Thomson
YIYoshikazu Inoue
Yoshikazu Inoue
KWKevin C. Wilson
Kevin C. Wilson
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.

1 August 2010 in Thorax
Verified
Journal Article
Open access
PDF file
NANadia Amara
Nadia Amara
DGDelphine Goven
Delphine Goven
FPFabienne Prost
Fabienne Prost
RMRachel Muloway
Rachel Muloway
BCBruno Crestani
Bruno Crestani
JBJorge Boczkowski
Jorge Boczkowski
Background Persistence of myofibroblasts is believed to contribute to the development of fibrosis in idiopathic pulmonary fibrosis (IPF). Transforming growth factor β1 (TGFβ1) irreversibly converts fibroblasts into pathological myofibroblasts, which express smooth muscle α-actin (α-SMA) and produce extracellular matrix proteins, such as procollagen I (α1). Reactive oxygen species produced by NADPH oxidases (NOXs) have been shown to regulate cell differentiation. It was hypothesised that NOX could be expressed in parenchymal pulmonary fibroblasts and could mediate TGFβ1-stimulated conversion of fibroblasts into myofibroblasts. Methods Fibroblasts were cultured from the lung of nine controls and eight patients with IPF. NOX4, α-SMA and procollagen I (α1) mRNA and protein expression, reactive oxygen species production and Smad2/3 phosphorylation were quantified, in the absence and in the presence of incubation with TGFβ1. Migration of platelet-derived growth factor (PDGF)-induced fibroblasts was also assessed. Results It was found that (1) NOX4 mRNA and protein expression was upregulated in pulmonary fibroblasts from patients with IPF and correlated with mRNA expression of α-SMA and procollagen I (α1) mRNA; (2) TGFβ1 upregulated NOX4, α-SMA and procollagen I (α1) expression in control and IPF fibroblasts; (3) the change in α-SMA and procollagen I (α1) expression in response to TGFβ1 was inhibited by antioxidants and by a NOX4 small interfering RNA (siRNA); (4) NOX4 modulated α-SMA and procollagen I (α1) expression by controlling activation of Smad2/3; and (5) NOX4 modulated PDGF-induced fibroblast migration. Conclusion NOX4 is critical for modulation of the pulmonary myofibroblast phenotype in IPF, probably by modulating the response to TGFβ1 and PDGF.

1 June 2011 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
RBRaphael borie
Raphael borie
CDC. Danel
C. Danel
MDM-P. Debray
M-P. Debray
CTC. Taille
C. Taille
MDM-C. Dombret
M-C. Dombret
BCB. Crestani
B. Crestani
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterised by alveolar accumulation of surfactant. It may result from mutations in surfactant proteins or granulocyte macrophage-colony stimulating factor (GM-CSF) receptor genes, it may be secondary to toxic inhalation or haematological disorders, or it may be auto-immune, with anti-GM-CSF antibodies blocking activation of alveolar macrophages. Auto-immune alveolar proteinosis is the most frequent form of PAP, representing 90% of cases. Although not specific, high-resolution computed tomography shows a characteristic “crazy paving” pattern. In most cases, bronchoalveolar lavage findings establish the diagnosis. Whole lung lavage is the most effective therapy, especially for auto-immune disease. Novel therapies targeting alveolar macrophages (recombinant GM-CSF therapy) or anti-GM-CSF antibodies (rituximab and plasmapheresis) are being investigated. Our knowledge of the pathophysiology of PAP has improved in the past 20 yrs, but therapy for PAP still needs improvement.

24 January 2018 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
LPLaurent Plantier
Laurent Plantier
ACAurélie Cazes
Aurélie Cazes
ADAnh-Tuan Dinh-Xuan
Anh-Tuan Dinh-Xuan
CBCatherine Bancal
Catherine Bancal
SMSylvain Marchand-Adam
Sylvain Marchand-Adam
BCBruno Crestani
Bruno Crestani
The clinical expression of idiopathic pulmonary fibrosis (IPF) is directly related to multiple alterations in lung function. These alterations derive from a complex disease process affecting all compartments of the lower respiratory system, from the conducting airways to the lung vasculature. In this article we review the profound alterations in lung mechanics (reduced lung compliance and lung volumes), pulmonary gas exchange (reduced diffusing capacity, increased dead space ventilation, chronic arterial hypoxaemia) and airway physiology (increased cough reflex and increased airway volume), as well as pulmonary haemodynamics related to IPF. The relative contribution of these alterations to exertional limitation and dyspnoea in IPF is discussed.

1 January 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
BCBruno Crestani
Bruno Crestani
JHJohn T Huggins
John T Huggins
MKMitchell Kaye
Mitchell Kaye
UCUlrich Costabel
Ulrich Costabel
IGIan Glaspole
Ian Glaspole
MKMichael Kreuter
Michael Kreuter

11 November 2016 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
RBRaphael borie
Raphael borie
LTLaure Tabèze
Laure Tabèze
GTGabriel Thabut
Gabriel Thabut
HNHilario Nunes
Hilario Nunes
Vincent CottinVincent Cottin
Vincent Cottin
BCBruno Crestani
Bruno Crestani
Telomerase reverse transcriptase (TERT) or telomerase RNA (TERC) gene mutation is a major monogenic cause of pulmonary fibrosis. Sequencing ofTERT/TERCgenes is proposed to patients with familial pulmonary fibrosis. Little is known about the possible predictors of this mutation and its impact on prognosis.We retrospectively analysed all the genetic diagnoses made between 2007–2014 in patients with pulmonary fibrosis. We evaluated the prevalence ofTERT/TERCdisease-associated variant (DAV), factors associated with a DAV, and the impact of the DAV on survival.237 patients with pulmonary fibrosis (153 with familial pulmonary fibrosis, 84 with telomere syndrome features without familial pulmonary fibrosis) were tested forTERT/TERCDAV. DAV was diagnosed in 40 patients (16.8%), including five with non-idiopathic interstitial pneumonia. Prevalence ofTERT/TERCDAV did not significantly differ between patients with familial pulmonary fibrosis or with only telomere syndrome features (18.2%versus16.4%). Young age, red blood cell macrocytosis, and low platelet count were associated with the presence of DAV; the probability of DAV was increased for patients 40–60 years. Transplant-free survival was lower with than withoutTERT/TERCDAV (4.2versus7.2 years; p=0.046).TERT/TERCDAV were associated with specific clinical and biological features and reduced transplant-free survival.